A real-world study of pyrotinib maleate in the treatment of brain metastases from HER2-positive solid tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058265

Enrollment

Unknown

Registered

2022-04-04

Start date

2022-03-31

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumors

Interventions

Experimental group:Pyrotinib

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 75 years; 2. HER2-positive (gene mutation, gene amplification, protein overexpression) solid tumor confirmed by histology or cytology; 3. Patients with brain metastases who plan to receive pyrotinib for treatment; 4. There are traceable medical history records during treatment.

Exclusion criteria

Exclusion criteria: 1. Not signing the informed consent; 2. Patients who are pregnant or breastfeeding; 3. The patient has serious concomitant diseases, or any other condition that the investigator considers the patient unsuitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival;	—

Secondary

Measure	Time frame
Objective Response Rate;Disease Control Rate;Overall Survival;	—

Countries

China

Contacts

Public ContactLi Xiaoyan

Beijing Tiantan Hospital, Capital Medical University

sharerha@126.com+86 13466383808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026